Prasad, Vinay
De Jesús, Kevin
Mailankody, Sham
Article History
First Online: 14 March 2017
Change Date: 3 April 2017
Change Type: Correction
Change Details: The originally published article contained a misrepresentation of the dose of pembrolizumab that most patients receive. "Consider, as an example, the anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab, a novel immunotherapeutic drug, for which administration to treat one person for 1 year (at a dose of 10 mg/kg) can now cost in excess of $1 million<sup>11</sup>" has been corrected to "For a 75 kg patient, the initially approved dose of 2 mg/kg every 3 weeks would cost approximately $121,000 per patient per year. That price goes to approximately $161,339 at the more recently FDA-approved 200 mg flat dose every 3 weeks, and at a dose of 10 mg/kg every 2 weeks, a dose not approved at the time of this writing but used in multiple published trials<sup>11–13</sup>, the cost for a 75 kg patient would be almost $1 million per year<sup>14</sup>." References to the trials that use the 10 mg/kg dose have been added and the other references updated throughout. These changes have been made in the online, PDF and print versions of this manuscript.
Competing interests
: The authors declare no competing financial interests.